These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1123 related items for PubMed ID: 26847964

  • 1. Levofloxacin, bismuth, amoxicillin and esomeprazole as second-line Helicobacter pylori therapy after failure of non-bismuth quadruple therapy.
    Song Z, Zhou L, Zhang J, He L, Bai P, Xue Y.
    Dig Liver Dis; 2016 May; 48(5):506-511. PubMed ID: 26847964
    [Abstract] [Full Text] [Related]

  • 2. Randomized Clinical Trial: Esomeprazole, Bismuth, Levofloxacin, and Amoxicillin or Cefuroxime as First-Line Eradication Regimens for Helicobacter pylori Infection.
    Fu W, Song Z, Zhou L, Xue Y, Ding Y, Suo B, Tian X, Wang L.
    Dig Dis Sci; 2017 Jun; 62(6):1580-1589. PubMed ID: 28391418
    [Abstract] [Full Text] [Related]

  • 3. Helicobacter pylori second-line rescue therapy with levofloxacin- and bismuth-containing quadruple therapy, after failure of standard triple or non-bismuth quadruple treatments.
    Gisbert JP, Romano M, Gravina AG, Solís-Muñoz P, Bermejo F, Molina-Infante J, Castro-Fernández M, Ortuño J, Lucendo AJ, Herranz M, Modolell I, Del Castillo F, Gómez J, Barrio J, Velayos B, Gómez B, Domínguez JL, Miranda A, Martorano M, Algaba A, Pabón M, Angueira T, Fernández-Salazar L, Federico A, Marín AC, McNicholl AG.
    Aliment Pharmacol Ther; 2015 Apr; 41(8):768-75. PubMed ID: 25703120
    [Abstract] [Full Text] [Related]

  • 4. Comparison of 10-day levofloxacin bismuth-based quadruple therapy and levofloxacin-based triple therapy for Helicobacter pylori.
    Wu TS, Hsu PI, Kuo CH, Hu HM, Wu IC, Wang SSW, Chen YH, Wu DC, Su WW, Kuo FC.
    J Dig Dis; 2017 Sep; 18(9):537-542. PubMed ID: 28644575
    [Abstract] [Full Text] [Related]

  • 5. Second-line rescue triple therapy with levofloxacin after failure of non-bismuth quadruple "sequential" or "concomitant" treatment to eradicate H. pylori infection.
    Gisbert JP, Molina-Infante J, Marin AC, Vinagre G, Barrio J, McNicholl AG.
    Scand J Gastroenterol; 2013 Jun; 48(6):652-6. PubMed ID: 23556551
    [Abstract] [Full Text] [Related]

  • 6. Second-line levofloxacin-based quadruple therapy versus bismuth-based quadruple therapy for Helicobacter pylori eradication and long-term changes to the gut microbiota and antibiotic resistome: a multicentre, open-label, randomised controlled trial.
    Liou JM, Jiang XT, Chen CC, Luo JC, Bair MJ, Chen PY, Chou CK, Fang YJ, Chen MJ, Chen CC, Lee JY, Yang TH, Yu CC, Kuo CC, Chiu MC, Chen CY, Shun CT, Hu WH, Tsai MH, Hsu YC, Tseng CH, Chang CY, Lin JT, El-Omar EM, Wu MS, Taiwan Gastrointestinal Disease and Helicobacter Consortium.
    Lancet Gastroenterol Hepatol; 2023 Mar; 8(3):228-241. PubMed ID: 36549320
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Cefuroxime, levofloxacin, esomeprazole, and bismuth as first-line therapy for eradicating Helicobacter pylori in patients allergic to penicillin.
    Song Z, Fu W, Zhou L.
    BMC Gastroenterol; 2019 Jul 25; 19(1):132. PubMed ID: 31345165
    [Abstract] [Full Text] [Related]

  • 9. Randomized comparison of two nonbismuth-containing rescue therapies for Helicobacter pylori.
    Hu TH, Chuah SK, Hsu PI, Wu DC, Tai WC, Chiu YC, Wu KL, Kuo CM, Hu ML.
    Am J Med Sci; 2011 Sep 25; 342(3):177-81. PubMed ID: 21804375
    [Abstract] [Full Text] [Related]

  • 10. Clinical evaluation of a ten-day regimen with esomeprazole, metronidazole, amoxicillin, and clarithromycin for the eradication of Helicobacter pylori in a high clarithromycin resistance area.
    Georgopoulos SD, Xirouchakis E, Martinez-Gonzalez B, Sgouras DN, Spiliadi C, Mentis AF, Laoudi F.
    Helicobacter; 2013 Dec 25; 18(6):459-67. PubMed ID: 23714140
    [Abstract] [Full Text] [Related]

  • 11. Comparison of sequential therapy and amoxicillin/tetracycline containing bismuth quadruple therapy for the first-line eradication of Helicobacter pylori: a prospective, multi-center, randomized clinical trial.
    Lee JY, Kim N, Park KS, Kim HJ, Park SM, Baik GH, Shim KN, Oh JH, Choi SC, Kim SE, Kim WH, Park SY, Kim GH, Lee BE, Jo Y, Hong SJ.
    BMC Gastroenterol; 2016 Jul 26; 16(1):79. PubMed ID: 27460100
    [Abstract] [Full Text] [Related]

  • 12. Rabeprazole, Minocycline, Amoxicillin, and Bismuth as First-Line and Second-Line Regimens for Helicobacter pylori Eradication.
    Song Z, Suo B, Zhang L, Zhou L.
    Helicobacter; 2016 Dec 26; 21(6):462-470. PubMed ID: 27060292
    [Abstract] [Full Text] [Related]

  • 13. Triple therapy with high-dose proton-pump inhibitor, amoxicillin, and doxycycline is useless for Helicobacter pylori eradication: a proof-of-concept study.
    Almeida N, Romãozinho JM, Donato MM, Luxo C, Cardoso O, Cipriano MA, Marinho C, Sofia C.
    Helicobacter; 2014 Apr 26; 19(2):90-7. PubMed ID: 24506175
    [Abstract] [Full Text] [Related]

  • 14. Efficacy of 1st-line bismuth-containing quadruple therapies with levofloxacin or clarithromycin for the eradication of Helicobacter pylori infection: A 1-week, open-label, randomized trial.
    Su J, Zhou X, Chen H, Hao B, Zhang W, Zhang G.
    Medicine (Baltimore); 2017 Feb 26; 96(7):e5859. PubMed ID: 28207505
    [Abstract] [Full Text] [Related]

  • 15. High-dose PPI-amoxicillin dual therapy with or without bismuth for first-line Helicobacter pylori therapy: A randomized trial.
    Yu L, Luo L, Long X, Liang X, Ji Y, Graham DY, Lu H.
    Helicobacter; 2019 Aug 26; 24(4):e12596. PubMed ID: 31111580
    [Abstract] [Full Text] [Related]

  • 16. The efficacy of second-line anti-Helicobacter pylori therapy using an extended 14-day levofloxacin/amoxicillin/proton-pump inhibitor treatment--a pilot study.
    Chuah SK, Tai WC, Hsu PI, Wu DC, Wu KL, Kuo CM, Chiu YC, Hu ML, Chou YP, Kuo YH, Liang CM, Chiu KW, Hu TH.
    Helicobacter; 2012 Oct 26; 17(5):374-81. PubMed ID: 22967121
    [Abstract] [Full Text] [Related]

  • 17. Two-week, high-dose proton pump inhibitor, moxifloxacin triple Helicobacter pylori therapy after failure of standard triple or non-bismuth quadruple treatments.
    Gisbert JP, Romano M, Molina-Infante J, Lucendo AJ, Medina E, Modolell I, Rodríguez-Tellez M, Gomez B, Barrio J, Perona M, Ortuño J, Ariño I, Domínguez-Muñoz JE, Perez-Aisa Á, Bermejo F, Domínguez JL, Almela P, Gomez-Camarero J, Millastre J, Martin-Noguerol E, Gravina AG, Martorano M, Miranda A, Federico A, Fernandez-Bermejo M, Angueira T, Ferrer-Barcelo L, Fernández N, Marín AC, McNicholl AG.
    Dig Liver Dis; 2015 Feb 26; 47(2):108-13. PubMed ID: 25454706
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Second-line rescue treatment of Helicobacter pylori infection: Where are we now?
    Lin TF, Hsu PI.
    World J Gastroenterol; 2018 Oct 28; 24(40):4548-4553. PubMed ID: 30386104
    [Abstract] [Full Text] [Related]

  • 20. High efficacy of 14-day triple therapy-based, bismuth-containing quadruple therapy for initial Helicobacter pylori eradication.
    Sun Q, Liang X, Zheng Q, Liu W, Xiao S, Gu W, Lu H.
    Helicobacter; 2010 Jun 28; 15(3):233-8. PubMed ID: 20557366
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 57.